ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
항바이러스제 시장 규모는 2025년 741억 2,000만 달러에서 2026년부터 2034년까지 CAGR 6.34%로 성장하여 2034년에는 1,288억 8,000만 달러에 달할 것으로 예측됩니다.
세계 항바이러스제 시장은 바이러스 감염증의 증가 추세와 효과적인 치료 솔루션에 대한 지속적인 수요에 힘입어 큰 폭의 성장이 예상됩니다. 독감, HIV, 간염 등 새로운 바이러스 병원체로 인해 전 세계가 어려움을 겪고 있는 가운데, 항바이러스제에 대한 수요는 그 어느 때보다 중요해지고 있습니다. 약제 내성을 가진 바이러스 균주의 출현은 치료 옵션을 더욱 복잡하게 만들고 있으며, 제약사들은 새로운 항바이러스제 연구개발에 대한 투자를 가속화하고 있습니다. 기존 및 신종 바이러스 위협에 대응하는 새로운 치료법의 도입으로 이러한 혁신에 대한 집중은 시장 확대를 촉진할 것으로 예상됩니다.
또한, 헬스케어와 백신 접종의 중요성에 대한 인식이 높아짐에 따라 항바이러스제 시장이 성장할 것으로 예상됩니다. 공중보건 정책으로 바이러스 감염에 대한 백신 접종의 필요성이 강조되는 가운데, 이를 보완하는 항바이러스제에 대한 수요는 증가할 것입니다. 항바이러스 치료와 백신 접종 프로그램의 통합은 특히 고위험군 집단에서 질병 관리와 통제의 전반적인 개선에 기여합니다. 또한, COVID-19 팬데믹과 같은 지속적인 세계 보건 위기는 항바이러스 연구의 중요성을 부각시키고, 항바이러스 약물 개발을 위한 개발 일정의 가속화와 자금 지원의 증가로 이어지고 있습니다.
또한, 생명공학 및 맞춤형 의료의 발전은 항바이러스제 시장의 미래를 형성할 것으로 예상됩니다. 특정 바이러스 작용 기전 및 환자 프로파일에 대응하는 표적 치료제의 개발이 진전되고 있으며, 보다 효과적이고 개별화된 치료 옵션의 가능성을 제공하고 있습니다. 또한, 여러 항바이러스제를 병용하여 효과를 높이고 내성을 감소시키는 병용요법이 바이러스 감염 관리의 중요한 전략으로 떠오르고 있습니다. 제약사, 연구기관, 의료 서비스 제공자 간의 협력은 이러한 혁신을 촉진하고 항바이러스제 시장이 진화하는 바이러스성 질환에 대응할 수 있도록 하는 데 필수적인 요소입니다.
목차
제1장 소개
제2장 주요 요약
제3장 시장 변수, 동향, 프레임워크
제4장 세계의 항바이러스제 시장 : 약물 종류별
제5장 세계의 항바이러스제 시장 : 용도별
제6장 세계의 항바이러스제 시장 : 유통 채널별
제7장 세계의 항바이러스제 시장 : 지역별
제8장 경쟁 구도
제9장 기업 개요
KSM
영문 목차
영문목차
The Antiviral Drugs Market size is expected to reach USD 128.88 Billion in 2034 from USD 74.12 Billion (2025) growing at a CAGR of 6.34% during 2026-2034.
The global antiviral drugs market is set to witness substantial growth, driven by the increasing prevalence of viral infections and the ongoing need for effective therapeutic solutions. As the world faces the challenges posed by emerging viral pathogens, including influenza, HIV, and hepatitis, the demand for antiviral medications is more critical than ever. The rise of drug-resistant viral strains further complicates treatment options, prompting pharmaceutical companies to invest in research and development of novel antiviral agents. This focus on innovation is expected to propel market expansion, as new therapies are introduced to combat existing and emerging viral threats.
Moreover, the growing awareness of preventive healthcare and the importance of vaccination are set to bolster the antiviral drugs market. As public health initiatives emphasize the need for vaccination against viral infections, the demand for antiviral drugs that complement these efforts will increase. The integration of antiviral therapies with vaccination programs can enhance overall disease management and control, particularly in high-risk populations. Additionally, the ongoing global health crises, such as the COVID-19 pandemic, have underscored the importance of antiviral research, leading to accelerated development timelines and increased funding for antiviral drug discovery.
In addition, advancements in biotechnology and personalized medicine are expected to shape the future of the antiviral drugs market. The development of targeted therapies that address specific viral mechanisms and patient profiles is gaining traction, offering the potential for more effective and tailored treatment options. Furthermore, the rise of combination therapies that utilize multiple antiviral agents to enhance efficacy and reduce resistance is becoming a key strategy in managing viral infections. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare providers will be essential in driving these innovations, ensuring that the antiviral drugs market remains responsive to the evolving landscape of viral diseases.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
MARKET SEGMENTATION
By Drug Class
Nucleoside Analogs
Protease Inhibitors
Polymerase Inhibitors
Others
By Application
HIV
Hepatitis
Influenza
Herpes
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
COMPANIES PROFILED
Gilead Sciences Inc, GlaxoSmithKline plc, BristolMyers Squibb Company, Merck Co Inc, Johnson Johnson, Roche Holding AG, Pfizer Inc, AstraZeneca plc, Novartis AG, Sanofi SA, Boehringer Ingelheim International GmbH, Mylan NV, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddys Laboratories Ltd
We can customise the report as per your requriements
TABLE OF CONTENTS
Chapter 1. PREFACE
1.1. Market Segmentation & Scope
1.2. Market Definition
1.3. Information Procurement
1.3.1 Information Analysis
1.3.2 Market Formulation & Data Visualization
1.3.3 Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1 List of Data Sources
Chapter 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segmental Outlook
2.3. Competitive Outlook
Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK
3.1. Market Lineage Outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Value Chain Analysis
3.4. Regulatory Framework
3.4.1 Standards & Compliance
3.4.2 Regulatory Impact Analysis
3.5. Market Dynamics
3.5.1 Market Drivers
3.5.2 Market Restraints
3.5.3 Market Opportunities
3.5.4 Market Challenges
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
Chapter 4. GLOBAL ANTIVIRAL DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)
4.1. Market Analysis, Insights and Forecast Drug Class
4.2. Nucleoside Analogs Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.3. Protease Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.4. Polymerase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 5. GLOBAL ANTIVIRAL DRUGS MARKET: BY APPLICATION 2022-2034 (USD MN)
5.1. Market Analysis, Insights and Forecast Application
5.2. HIV Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.4. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.5. Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 6. GLOBAL ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)
6.1. Market Analysis, Insights and Forecast Distribution Channel
6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
Chapter 7. GLOBAL ANTIVIRAL DRUGS MARKET: BY REGION 2022-2034(USD MN)
7.1. Regional Outlook
7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.2.1 By Drug Class
7.2.2 By Application
7.2.3 By Distribution Channel
7.2.4 United States
7.2.5 Canada
7.2.6 Mexico
7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.3.1 By Drug Class
7.3.2 By Application
7.3.3 By Distribution Channel
7.3.4 United Kingdom
7.3.5 France
7.3.6 Germany
7.3.7 Italy
7.3.8 Russia
7.3.9 Rest Of Europe
7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.4.1 By Drug Class
7.4.2 By Application
7.4.3 By Distribution Channel
7.4.4 India
7.4.5 Japan
7.4.6 South Korea
7.4.7 Australia
7.4.8 South East Asia
7.4.9 Rest Of Asia Pacific
7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.5.1 By Drug Class
7.5.2 By Application
7.5.3 By Distribution Channel
7.5.4 Brazil
7.5.5 Argentina
7.5.6 Peru
7.5.7 Chile
7.5.8 South East Asia
7.5.9 Rest of Latin America
7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
7.6.1 By Drug Class
7.6.2 By Application
7.6.3 By Distribution Channel
7.6.4 Saudi Arabia
7.6.5 UAE
7.6.6 Israel
7.6.7 South Africa
7.6.8 Rest of the Middle East And Africa
Chapter 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments
8.2. Company Categorization
8.3. Supply Chain & Channel Partners (based on availability)
8.4. Market Share & Positioning Analysis (based on availability)
8.5. Vendor Landscape (based on availability)
8.6. Strategy Mapping
Chapter 9. COMPANY PROFILES OF GLOBAL ANTIVIRAL DRUGS INDUSTRY
